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Abstarct. TRPA1 is an ankyrin receptor of TRP family. It is a non-selective, calcium-permeable 
cation channel that is highly expressed by a subset of small diameter sensory neurons with cell 
bodies in the dorsal root, trigeminal, nodose and jugular ganglia. In the last time information 
about the role of TRPA1 in pain and cold sensitivity, as well as in the formation and maintenance 
of inflammation is increasing in scientific literature. Given this information, the interest for search 
and study of pharmacological agents, which selectively blocked of TRPA1 and reduced the 
severity of pain and inflammation is increasing. 
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Pain is a complaint for appeal in the primary 
healthcare departments, which mainly the load of the 
treatment of patients with different types of pain 
syndromes. Besides, costs of treating chronic pain 
and acute pain relief steadily increase. It is known 
that about 90% of all diseases are associated with 
pain [7].  
International epidemiological study showed that 
49.2% patients of primary healthcare departments 
had complaint of pain. In according to European 
epidemiological study 19% of adult Europeans suffer 
from pain of moderate to severe intensity, which 
reduces the quality of life, breaking the everyday 
routine and work. About half of such patients have 
not received appropriate treatment [4]. 
According to the Russian Association for the 
study of pain the prevalence of chronic pain in Russia 
is average 34.3 cases per 100 persons. More than 
40% patients with chronic pain say that pain reduces 
significantly the quality of their life [1, 2].  
Among the approaches used to adjust the use of 
molecular methods for screening, at the cellular, 
organ, and organism levels integral. 
Today narcotic analgesics and non-steroid anti-
inflammatory drugs use for treatment of pain more 
often. However, both of it have many side effects that 
limit its widespread and long term use in clinical 
practice.  
Thus, today pharmaceutical market doesn’t have 
analgesic drugs that completely satisfy the 
requirements of efficiency and safety. That’s why the 
most promising solution is to provide new analgesic 
drug based on selective inhibition of TRPA1. 
TRPA1 is highly expressed by a subset of small 
diameter sensory neurons with cell bodies in the 
dorsal root, trigeminal, nodose and jugular ganglia 
and immediately perceives painful stimuli and 
inflammatory mediators [6, 8]. The results of their 
research some authors have reported an increase in 
expression of TRPA1 in pathological conditions, for 
example, inflammation, neuropathy [3, 5]. Today 
data is increasingly appearing in the literature on the 
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possible use of TRPA1 selective inhibitors for 
treatment of pain syndrome.  
The goal of research is study of the analgesic 
activity of a selective inhibitor of TRPA1 receptors 
compared with the reference drug ketorolac. 
Materials and methods. Experiments were 
performed on male white laboratory mice weighing 
20-22 g. Study of the analgesic activity of TRPA1 
selective inhibitor was performed in the test «hot 
plate» in intragastric and intramuscular routes of 
administration. Ketorolac was used as a comparison 
drug. Intact animals were placed on a heated to 55 °C 
plate and fixed the time in seconds before the first 
lick their paws.  
All the animals were divided into 3 groups of 
each 2 series: 
Group I (control): series 1 – intragastric 
administration of placebo (normal saline) in a volume 
of 0.1 ml / 10 g body weight (n = 20). 
Series 2 – intramuscular injection of placebo 
(normal saline) in a volume of 0.1 ml / 10 g body 
weight (n = 20). 
Group II: series 1 – intragastric administration of 
ketorolac in a dose of 3.48 mg / kg (n = 20). 
Series 2 – intramuscular injection of ketorolac in 
a dose of 3.48 mg / kg (n = 20). 
Group II: series 1 – intragastric administration of 
TRPA1 selective inhibitor (ZB-010621 substance) in 
a dose of 3 mg / kg (n = 20). 
Series 2 – intramuscular injection of TRPA1 
selective inhibitor (ZB-010621 substance) in a dose 
of 3 mg / kg (n = 20). 
Then, at 30, 60, 90 and 120 minutes after the 
administration of substances the animals were placed 
again at the hot plate and the time in seconds was 
fixed before the start of the animal licking paws. 
Data adequacy of the study were determined by 
methods of descriptive and analytical statistics with 
the definition of arithmetical mean (M), their 
standard mean square error (± m) and P-value (p), 
calculated using the T-test for groups with different 
dispersion. Differences were estimated as significant 
at p <0.05. Statistical calculations were performed 
using SPSS 21 software. 
Results. In intragastric administration of the test 
substances has been found that a dose of ketorolac 
3.48 mg/kg, and TRPA1 selective inhibitor (ZB-
010621 substance) in a dose of 3 mg/kg exhibit its 
greatest analgesic activity after 60 minutes from the 
time of administration (Table 1).  
Table 1 
The results of «hot plate» test on male white laboratory mice (M±m) 
Time 
Control group Ketorolac group ZB-010621 substance group 
intragastric intramuscular intragastric intramuscular intragastric intramuscular 
Depature 7.93±0.23 7.7±0.67 7.42±0.49 6.10±0.81 7.60±0.52 8.21±0.81 
30 min 8.54±0.72 9.25±0.92 13.57±0.59* 16.41±1.01* 18.81±0.76** 22.19±1.12** 
60 min 9.5±0.88 9.73±0.9 15.91±0.61* 13.74±1.16* 21.7±0.82** 19.57±1.43** 
90 min 9.75±0.90 8.4±0.71 12.56±0.55 11.82±1.37 17.63±0.79** 17.44±1.79** 
120 min 9.39±0.90 8.2±0.70 8.34±0.54 9.21±0.92 13.75±0.71** 14.78±0.92** 
Note: * - significant difference from control group (р<0.05), ** - significant difference from Ketorolac group (р<0.05). 
However, TRPA1 selective inhibitor (ZB-
010621 substance) showed a pronounced analgesic 
action compared to ketorolac (21.7 ± 0.82 sec and 
15.91 ± 0.61 sec, respectively). Moreover, in the 
group of ketorolac at 90 minutes from the 
introduction the arithmetical mean of time from the 
animals were placed on a heated to 55 °C plate till 
the moment licking paws were not significantly 
different from the control group (12.56 ± 0.55 sec 
and 9.75 ± 0.90, respectively), whereas the analgesic 
effect of a TRPA1 selective inhibitor (ZB-010621 
substance) lasted for 90 minutes, and 120 minutes 
following administration of substance (17.63 ± 0.79 
seconds and 13.75 ± 0.71 sec respectively, p <0.05 
compared with ketorolac). 
In intramuscular administration of the test 
substances ketorolac and TRPA1 selective inhibitor 
(ZB-010621 substance) exhibit analgesic activity 
maximum at 30 minutes after administration (16.41 ± 
1.01 sec and 22.19 ± 1.12 respectively). However, 
TRPA1 selective inhibitor (ZB-010621 substance) 
exceeds ketorolac not only in the expression of 
analgesic activity, but also its duration, as evidenced by 
the longer time from the moment from the animals were 
placed on a heated to 55 °C plate till the moment licking 
paws in the group of TRPA1 selective inhibitor (ZB-
010621 substance) compared with the control group 
after 60, 90 and 120 min, while the action of ketorolac 
by the ends 90 minutes (Table 1). 
Conclusions. Thus, TRPA1 selective inhibitor 
(ZB-010621 substance) in the «hot plate» test 
exceeds ketorolac not only in the expression of 
analgesic activity, but also the duration of its as in 
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intragastric and intramuscular administration of test 
substances. 
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